Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | Optimizing blinatumomab for B-ALL

Rachel Rau • 31 Aug 2021
SOHO 2021
Acute Lymphoblastic Leukemia General Leukemia Antibodies Blinatumomab
AALL1731

Rachel Rau, MD, of Baylor College of Medicine, Houston, TX, discusses the optimal use of blinatumomab for the treatment of B-cell acute lymphoblastic leukemia (B-ALL), commenting on how it could be used to achieve undetectable measurable residual disease (MRD). Dr Rau also talks on the Phase III AALL1731 trial (NCT03914625) currently investigating blinatumomab in combination with chemotherapy for newly diagnosed (B-ALL). This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

Disclosures

Rachel Rau, MD, has participated in consultancy work with Jazz and Servier.

More from Rachel Rau

4:24
Updates on BiTEs for B-ALL
Rachel Rau • 31 Aug 2021
1:33
The importance of optimizing treatment of B-ALL at induction
Rachel Rau • 31 Aug 2021
3:04
B-ALL patient selection for treatment with blinatumomab
Rachel Rau • 31 Aug 2021

Related Videos

0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:44
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard • 11 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
3:29
PTCy as GvHD prophylaxis: side effects, optimizing the dose, and the effect of dose-reduction
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals